Published in J Neurol on November 18, 2009
Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health Qual Life Outcomes (2010) 1.00
Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study. J Neurol (2012) 0.84
Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery. BMC Neurol (2011) 0.82
Treatment satisfaction in multiple sclerosis. Int J MS Care (2014) 0.80
Adverse events of interferon beta-1a: a prospective multi-centre international ICH-GCP-based CRO-supported external validation study in daily practice. PLoS One (2011) 0.79
Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines. Patient Prefer Adherence (2016) 0.78
[Combined retinal artery and vein occlusions associated with interferon beta therapy]. Ophthalmologe (2012) 0.77
Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study). Health Qual Life Outcomes (2017) 0.75
Quality of life in relapsing-remitting multiple sclerosis patients receiving CinnoVex compared with Avonex. J Res Pharm Pract (2016) 0.75
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs. CNS Drugs (2017) 0.75
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
A health-related quality of life measure for multiple sclerosis. Qual Life Res (1995) 3.46
Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis. J Neurol Sci (2004) 1.53
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol (2001) 1.35
Factors associated with health-related quality of life in multiple sclerosis. Can J Neurol Sci (2007) 1.29
A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci (2003) 1.03
Influence of Interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes (2006) 1.01
Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment. Mult Scler (2002) 1.00
Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology (2000) 0.97
Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol (2000) 0.97
Quality of life during the first 6 months of interferon-beta treatment in patients with MS. Mult Scler (2000) 0.96
Association of factors influencing health-related quality of life in MS. Acta Neurol Scand (2006) 0.93
Treatment with interferon beta-1b improves quality of life in multiple sclerosis. Can J Neurol Sci (1999) 0.89
Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment. Mult Scler (2006) 0.87
Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis. Mult Scler (2003) 0.83
Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis (2012) 3.86
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Effect of obesity on the outcome of kidney transplantation: a 20-year follow-up. Transplantation (2011) 1.77
Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res Hum Retroviruses (2006) 1.67
Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant (2004) 1.50
Susac syndrome in four male patients. Retina (2006) 1.41
Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med (2006) 1.15
Asymptomatic small fiber neuropathy in diabetes mellitus: investigations with intraepidermal nerve fiber density, quantitative sensory testing and laser-evoked potentials. J Neurol (2011) 1.03
No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS One (2008) 1.01
Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. Neurobiol Aging (2011) 0.99
Concomitant analysis of arterial, venous, and CSF flows using phase-contrast MRI: a quantitative comparison between MS patients and healthy controls. J Cereb Blood Flow Metab (2013) 0.98
Neurofilament ELISA validation. J Immunol Methods (2009) 0.96
Mitochondrial enzymes discriminate between mitochondrial disorders and chronic fatigue syndrome. Mitochondrion (2011) 0.95
High disease impact of myotonic dystrophy type 2 on physical and mental functioning. J Neurol (2011) 0.90
Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial. Mult Scler (2010) 0.89
Expression of human amyloid precursor protein in rat cortical neurons inhibits calcium oscillations. J Neurosci (2009) 0.88
Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine (2013) 0.88
The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas? Neurology (2012) 0.87
New candidate loci for multiple sclerosis susceptibility revealed by a whole genome association screen in a Belgian population. J Neuroimmunol (2003) 0.86
Helping hands: a cluster randomised trial to evaluate the effectiveness of two different strategies for promoting hand hygiene in hospital nurses. Implement Sci (2011) 0.86
Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young. Clin Neurol Neurosurg (2012) 0.86
Adherence to monthly online self-assessments for short-term monitoring: a 1-year study in relapsing-remitting multiple sclerosis patients after start of disease modifying treatment. Patient Prefer Adherence (2013) 0.86
The characteristics of LTP induced in hippocampal slices are dependent on slice-recovery conditions. Learn Mem (2006) 0.85
Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant (2004) 0.85
Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational study. Health Qual Life Outcomes (2014) 0.83
Neuropathology of human and experimental TSP/HAM: a critical review. Acta Neurol Belg (2002) 0.83
The Lively Legs self-management programme increased physical activity and reduced wound days in leg ulcer patients: Results from a randomized controlled trial. Int J Nurs Stud (2011) 0.83
Anti-N-methyl-D-aspartate receptor encephalitis with favorable outcome despite prolonged status epilepticus. Neurocrit Care (2013) 0.82
Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery. BMC Neurol (2011) 0.82
Fatal rhinocerebral mucormycosis with intracavernous carotid aneurysm and thrombosis: a late complication of transsphenoidal surgery? Acta Neurol Belg (2012) 0.81
Interleukin-12 p40 polymorphism and susceptibility to multiple sclerosis. Ann Neurol (2002) 0.80
Effects of a postqualification course in palliative care. J Adv Nurs (2005) 0.80
Cue-responding behaviours of oncology nurses in video-simulated interviews. J Adv Nurs (2007) 0.79
Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome. J Neurochem (2012) 0.79
Adverse events of interferon beta-1a: a prospective multi-centre international ICH-GCP-based CRO-supported external validation study in daily practice. PLoS One (2011) 0.79
Inhibition of neuronal calcium oscillations by cell surface APP phosphorylated on T668. Neurobiol Aging (2010) 0.78
Neuropathology of two Brazilian autopsied cases of tropical spastic paraparesis / HTLV-I associated myelopathy (TSP/HAM) of long evolution. Arq Neuropsiquiatr (2002) 0.77
Estimating life expectancy and related probabilities in screen-detected breast cancer patients with restricted follow-up information. Stat Med (2004) 0.77
Ventricular arrhythmia in a male MS patient on fingolimod. Acta Neurol Belg (2014) 0.77
Remitting/relapsing idiopathic hypertrophic spinal pachymeningitidis: comprehensive imaging work-up and MR monitoring. Eur Radiol (2004) 0.76
Absence of recurrent stroke after percutaneous closure of patent foramen ovale despite residual right-to-left cardiac shunt assessed by transcranial Doppler. Arch Cardiovasc Dis (2008) 0.76
Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program. Acta Neurol Belg (2014) 0.75
Labyrinthectomy changes T-type calcium channels in vestibular neurones of the guinea pig. Neuroreport (2003) 0.75
Reply: To PMID 21901859. Pediatr Pulmonol (2012) 0.75
Tyrosine phosphorylation of rabphilin during long-lasting long-term potentiation. Neurosci Lett (2006) 0.75
The usefulness of the Staff-Patient Interaction Response Scale for palliative care nursing for measuring the empathetic capacity of nursing students. J Prof Nurs (2008) 0.75